Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2026-01-08 @ 12:04 PM
Study NCT ID:
NCT02357433
Status:
TERMINATED
Last Update Posted:
2018-07-06
First Post:
2015-01-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mortality Reduction in Septic Shock by Plasma Adsorption
Sponsor:
Francisco Colomina Climent
Organization:
Study Overview
Official Title:
Reduccion de la Mortalidad Mediante Plasma-Adsorción en Shock séptico (ROMPA)
Status:
TERMINATED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Circumstances beyond the course of the trial have produced a change in the conditions of recruitment unacceptable to the ROMPA researchers
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ROMPA
Brief Summary:
The study objective is to clarify whether the application of high doses CPFA (Coupled Plasma-Filtration Adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in intensive care unit (ICU).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: